AU2023250031A1 - Combination therapy for treating cancer - Google Patents

Combination therapy for treating cancer Download PDF

Info

Publication number
AU2023250031A1
AU2023250031A1 AU2023250031A AU2023250031A AU2023250031A1 AU 2023250031 A1 AU2023250031 A1 AU 2023250031A1 AU 2023250031 A AU2023250031 A AU 2023250031A AU 2023250031 A AU2023250031 A AU 2023250031A AU 2023250031 A1 AU2023250031 A1 AU 2023250031A1
Authority
AU
Australia
Prior art keywords
azd5305
pharmaceutically acceptable
acceptable salt
enzalutamide
prostate cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023250031A
Other languages
English (en)
Inventor
Mark R ALBERTELLA
Jessica S BROWN
Sabina Chiara Cosulich
Elisabetta LEO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2023250031A1 publication Critical patent/AU2023250031A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2023250031A 2022-04-07 2023-04-06 Combination therapy for treating cancer Pending AU2023250031A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263362613P 2022-04-07 2022-04-07
US63/362,613 2022-04-07
PCT/EP2023/059130 WO2023194530A1 (en) 2022-04-07 2023-04-06 Combination therapy for treating cancer

Publications (1)

Publication Number Publication Date
AU2023250031A1 true AU2023250031A1 (en) 2024-11-14

Family

ID=86226547

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023250031A Pending AU2023250031A1 (en) 2022-04-07 2023-04-06 Combination therapy for treating cancer

Country Status (11)

Country Link
US (1) US20250213556A1 (cg-RX-API-DMAC7.html)
EP (1) EP4504182A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025511402A (cg-RX-API-DMAC7.html)
KR (1) KR20240170957A (cg-RX-API-DMAC7.html)
CN (1) CN119212702A (cg-RX-API-DMAC7.html)
AU (1) AU2023250031A1 (cg-RX-API-DMAC7.html)
CA (1) CA3254949A1 (cg-RX-API-DMAC7.html)
IL (1) IL316017A (cg-RX-API-DMAC7.html)
MX (1) MX2024012392A (cg-RX-API-DMAC7.html)
TW (1) TW202404661A (cg-RX-API-DMAC7.html)
WO (1) WO2023194530A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240325384A1 (en) * 2023-03-31 2024-10-03 Astrazeneca Ab Dosing regimen
TW202600137A (zh) * 2024-04-04 2026-01-01 美商輝瑞股份有限公司 於使用parp抑制劑的治療作為預測性生物標記之tmprss2-erg和rbi及使用parp抑制劑之治療方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0699754B2 (en) 1994-08-12 2009-08-12 The University of Utah Research Foundation Method for diagnosing a predisposition for breast and ovarian cancer
DE69521002T3 (de) 1994-08-12 2010-02-25 The University Of Utah Research Foundation, Salt Lake City Mutationen des mit 17q verbundenen Ovarial- und Brustkrebs Empfindlichkeitsgens
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
TWI837403B (zh) 2019-07-19 2024-04-01 瑞典商阿斯特捷利康公司 化學化合物

Also Published As

Publication number Publication date
JP2025511402A (ja) 2025-04-15
MX2024012392A (es) 2024-11-08
CN119212702A (zh) 2024-12-27
WO2023194530A1 (en) 2023-10-12
TW202404661A (zh) 2024-02-01
IL316017A (en) 2024-11-01
EP4504182A1 (en) 2025-02-12
US20250213556A1 (en) 2025-07-03
KR20240170957A (ko) 2024-12-05
CA3254949A1 (en) 2023-10-12

Similar Documents

Publication Publication Date Title
CA2861056A1 (en) Combination therapy (vemrufenib and a mdm2 inhibitor) for the treatment proliferative disorders
US20250213556A1 (en) Combination therapy for treating cancer
CN119486713A (zh) 尼罗加司他治疗
AU2023248685A1 (en) Combination therapy for treating cancer
TW202425976A (zh) 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
KR20220124739A (ko) 암의 치료를 위한 병용 요법
US20250228847A1 (en) Combination therapy for treating cancer
JP2025522390A (ja) 癌を処置するための併用療法
AU2005269052A1 (en) Combination comprising a BCRP inhibitor and 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide
JP2026515235A (ja) 癌を治療するためのparp1阻害剤と選択的エストロゲン分解薬の併用
US20250170146A1 (en) Niraparib and abiraterone acetate plus prednisone to improve clinical outcomes in patients with metastatic castration-resistant prostate cancer and hrr alterations
TW202600137A (zh) 於使用parp抑制劑的治療作為預測性生物標記之tmprss2-erg和rbi及使用parp抑制劑之治療方法
US20090062246A1 (en) Therapeutic treatment-014
KR20240056487A (ko) 고형 종양을 치료하기 위한 약제학적 조성물
KR20260020107A (ko) 다발성 경화증을 치료하기 위한 btk 억제제